 

Active ingredient: Atomoxetine Hydrochloride 

 

Form/Route: Capsules/Oral 

 

Recommended studies: 2 studies 

 

1. Type of study: Fasting 
Design: Single-dose, two-way crossover in-vivo 

Strength: 60 mg 

Subjects: Normal healthy males and females, general population 

Additional Comments: 60 mg is studied because higher doses may cause unacceptable side-
effects in normal healthy subjects 




______________________________________________________________________________ 

 

2. Type of study: Fed 
Design: Single-dose, two-way crossover in-vivo 

Strength: 60 mg 

Subjects: Normal healthy males and females, general population 

Additional comments: Please see comment above. 




______________________________________________________________________________ 

 

Analytes to measure (in appropriate biological fluid): Atomoxetine in plasma 

 

Bioequivalence based on (90% CI): Atomoxetine 

 

Waiver request of in-vivo testing: 5**, 10, 18, 25, 40, 80 and 100 mg based on (i) 

acceptable bioequivalence studies on the 60 mg strength, (ii) proportionally similar across 

all strengths, and (iii) acceptable in vitro dissolution testing of all strengths. 

 

** The 5 mg strength of STRATTERA™ is currently not marketed. If a firm is interested in seeking ap-
proval for this strength, please submit a citizen petition requesting the U.S. Food and Drug Administra-
tion (FDA) make a determination that this particular strength was not withdrawn for reasons of safety or 
effectiveness, or check the Federal Register for a previously submitted citizen petition. Submission of the 
citizen petition to the FDA should be done prior to an ANDA submission. 

 

Dissolution test method and sampling times: 

 

Please note that a Dissolution Methods Database is available to the public at the OGD website at 
http://www.fda.gov/cder/ogd/index.htm. Please find the dissolution information for this product at this 
website. Please conduct comparative dissolution testing on 12 dosage units each of all strengths of the test 
and reference products. Specifications will be determined upon review of the application. 

 


